{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:13:33Z","timestamp":1788902013681,"version":"build-2803163510"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    A 23-year-old man with metastatic extraskeletal Ewing sarcoma, who was unable to tolerate standard-dose chemotherapy, received 1 cycle of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAP-2286, followed by 2 cycles of reduced-dose ifosfamide\/epirubicin\/mesna chemotherapy. Follow-up\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAP-2286 PET\/CT at 2 months showed a marked metabolic response with reduced tumor size and tracer uptake. No adverse events were observed. The patient remained symptom-free at 2 months. This case suggests that\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAP-2286 combined with chemotherapy may have clinical utility in advanced Ewing sarcoma.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006639","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:01:07Z","timestamp":1788901267000},"page":"952-954","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Combined 177Lu-FAP-2286 Therapy and Chemotherapy in Extraskeletal Ewing Sarcoma With Multiple Metastases"],"prefix":"10.1097","volume":"51","author":[{"given":"Lixian","family":"Mou","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/pbc.20820","article-title":"Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial","volume":"47","author":"Juergens","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"e243495","DOI":"10.1136\/bcr-2021-243495","article-title":"Dilemma in diagnosis and management of rare primary pleural Ewing\u2019s sarcoma with synchronous limited metastatic disease","volume":"14","author":"Bhaskaran","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","article-title":"Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours","volume":"55","author":"Dohi","year":"2009","journal-title":"Histopathology"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1007\/s00259-021-05374-4","article-title":"Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET\/CT","volume":"48","author":"Koerber","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cpet.2023.02.006","article-title":"Fibroblast activation protein inhibitor theranostics: preclinical combination treatment","volume":"18","author":"L\u00fcckerath","year":"2023","journal-title":"PET Clin"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/biomimetics10060394","article-title":"Radionuclide-labeled biomaterials: a novel strategy for tumor-targeted therapy","volume":"10","author":"Zhang","year":"2025","journal-title":"Biomimetics"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.semnuclmed.2025.06.010","article-title":"[177Lu]Lu-FAPI radioligand therapy: emerging horizons and clinical promise in solid tumors: a comprehensive review","volume":"55","author":"Al-Ibraheem","year":"2025","journal-title":"Semin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:01:08Z","timestamp":1788901268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006639","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"2026-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}